Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 149

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 6
Chunk 149
---
. Reed                                                                                                46      Takeda Pharmaceutical Company Limited                                                                 21                                    19      5          
  Olivier Bohuon (3)                                                                                              37      Takeda Pharmaceutical Company Limited                                                                  3                                     3      30         

_____________

Notes:

(1) Compensation expense related to Restricted Stock Unit awards are recognized over multiple fiscal years, depending on the length of the period eligible for earning compensation. This column shows amounts recognized as expenses during the fiscal year ended March 31, 2025.

(2) The amounts represent expenses for adjustments on compensation, paid to External Directors residing outside of Japan, to account for the impact of foreign exchange rates.

(3) Olivier Bohuon passed away on May 5, 2024 and his term as director terminated on the same date.

Table of Contents

Share-based Compensation Payments

We maintain certain share-based compensation payment plans for the benefit of our directors and certain of our employees. In the fiscal years ended March 31, 2023, 2024 and 2025, we recorded total compensation expense related to our share-based payment plans of JPY 61.0 billion. JPY 71.5 billion and JPY 73.6 billion, respectively, in our consolidated statements of profit or loss. For detailed information about our share-based compensation plans, including our stock option plan, stock incentive plan, phantom stock appreciation rights and restricted stock units, see Note 28 to our audited consolidated financial statements.

Director's Compensation Policy

Please see “ Item 6. A Directors and Senior Management” for a list of Takeda’s directors and their positions, including their status as “ Internal” or “ External” directors and membership on the Audit & Supervisory Committee.

Since there are no Internal Directors who are Audit & Supervisory Committee Members in the Company, they are referred to simply as "Internal Directors" hereinafter in this section.

1. Guiding Principles

The following are the guiding principles of the Company's compensation system for Directors to achieve our management objectives under the corporate governance code:

To attract, retain and motivate managerial talent to realize our Vision

To increase corporate value through optimization of the Company’s mid- and long-term performance, while reinforcing our patient first values

To be closely linked with company performance, highly transparent and objective

To support a strong alignment with the interests of shareholders and enhance a shareholder-oriented management perspective

To encourage Directors’ spirit of challenge aligned with the values of Takeda-ism, perseverance

To